Cumberland Pharmaceuticals reports Phase 2a safety data for ifetroban in systemic sclerosis

Cumberland Pharmaceuticals released top‑line results from its 12‑month Phase 2a ASSIST‑SSc trial of oral ifetroban in systemic sclerosis patients. The drug was generally well tolerated, with gastrointestinal and mild bleeding events more common than with placebo, but the study was not powered to assess efficacy and showed no clear benefit over placebo. The company will submit a clinical study report to the FDA and conduct additional biomarker and cardiac imaging analyses. Investors reacted negatively, sending the stock sharply lower in after‑hours trading.

According to material 4, the after‑hours share price fell 10.6% to $7.59, reflecting investor disappointment that the trial did not deliver efficacy signals. The drop underscores the market’s sensitivity to clinical‑development milestones for biotech firms.

  • 1The trial enrolled 31 patients receiving ifetroban and 10 receiving placebo.
  • 2Ifetroban was generally well tolerated, with mostly mild gastrointestinal and bleeding‑related adverse events.
  • 3The study was not designed or statistically powered to evaluate efficacy.
  • 4Cumberland plans to submit the clinical study report to the FDA and conduct follow‑up biomarker and cardiac imaging studies.
  • 5After‑hours trading price fell to $7.59.
  • Material 3 reports an 11% after‑hours decline, material 4 reports 10.6%, and material 5 reports 17.55% – conflicting figures for the same stock‑price move.

Sources